Kornimate/medical-research-clean huggingface dataset:
effects of tdcs with physical therapy on rehabilitation in parkinson's disease

Conditions: Parkinson Disease

Summary: the present study aims to investigate the effect of transcranial direct current stimulation (tdcs) associated with physiotherapy in parkinson´s rehabilitation. previous studies showed that tdcs could reduce the bradykinesia, one of the symptom of parkinson disease. in this way, this study will combine tdcs with physiotherapy in order to enhance the motor rehabilitation and the quality of life.

12 patients were participated of this study.after screening to check the eligibility criteria and giving informed consent, they were randomized in two groups. all patients were submitted to a 10 therapeutic sessions that occurred 3 times per week. before, immediately after and 1 month after the last session patients were submitted to an evaluation with the follow tests: unified parkinson´s disease rating scale(updrs), jebsen taylor test (jtt) and parkinson's disease quality of life (pdql). furthermore, before and after each session the patients were submitted to transcranial magnetic stimulation (tms) to evaluate cortical excitability through motor threshold and motor evoked potential. in experimental sessions, the subjects always received physiotherapy with conventional techniques, the protocol followed the clinical practice guideline for physical therapy in parkinson disease with the royal dutch society therapy. during tdcs protocol the patients seated in a comfortable chair with head and arm rests. continuous current was applied using a pair of saline-soaked surface sponge electrodes (surface 35 cm2), the anode electrode was placed over the primary motor cortex and cathode above contralateral orbit. tdcs was applied of twice stimulation of 13 minutes with 20 minutes of interval between them and a current strength of 1ma. sham tdcs was applied by current flow of 30s.

Eligibility criteria:
inclusion criteria: parkinson disease comproved by a neurologist regular treatment with dopamine or other drugs against parkinson - exclusion criteria: pregnant history of convulsion metal implant in the region of skull or face change in medication during the study realize other physical therapy in the same time of the study previous surgery for parkinson disease -

Keywords: parkinson, rehabilitation, tdcs
the role of bemer and kinesiotape in increasing the effectiveness of physiotherapy and rehabilitation program after videothoracoscopy surgery

Conditions: Pain, Post Operative

Summary: the literature indicates that postoperative pulmonary complications are seen when pain is not treated effectively after videothoracoscopy surgery (vats). after surgery, physiotherapy and rehabilitation approaches are applied to prevent complications. bio-electro-magnetic-energy-regulation (bemer) therapy uses low-frequency electromagnetic energy to regulate vasomotion in capillaries and increase microcirculation. bemer therapy can be applied together with physiotherapy and rehabilitation. the aim of this study is to investigate the effectiveness of bemer application, which is added to the physiotherapy and rehabilitation program applied after videothoracoscopy surgery.


Eligibility criteria:
inclusion criteria: * inclusion criteria for the study were to have undergone vats lobectomy and to be aged between 18 and 75 years. exclusion criteria: * presence of pacemaker, severe cardiac failure, severe arrhythmia * those with cooperative disorders * presence of neurological or orthopedic problems affecting the extremities * those with severe psychiatric disorders * failure to perform the operation according to the result of intraoperative tumor staging * patients who go out of the standard analgesia protocol * patients who were taken back from the service to the intensive care unit
mechanisms of diabetes control after weight loss surgery, sub-study #1

Conditions: Gastric Bypass Surgery; Gastric Banding; Type 2 Diabetes

Summary: gastric bypass (gbp) and laparoscopic adjustable banding (agb) are common procedures that can result in significant weight loss and significantly improve type 2 diabetes in 40-80% of cases. the mechanism and time course of these changes have not been well studied and are poorly understood. the primary aim of this study is to investigate the potential weight-independent mechanisms of diabetes remission after gbp, by comparing gbp and agb subjects after similar weight loss.

all participants will be tested before and then after 10 and 20-30% weight loss after either gbp or agb surgery. subjects will undergo an oral glucose tolerance test (ogtt) an isoglycemic intravenous glucose test (ivgt) to assess the incretin effect, a measure of insulin sensitivity by an intravenous insulin sensitivity test (ivgtt) and body composition measurements.

Eligibility criteria:
inclusion criteria: * obese type 2 diabetes individuals scheduled to undergo bariatric surgery by either gastric banding or gastric bypass surgery

Keywords: bariatric gastric bypass gastric banding, type 2 diabetes incretins glp-1 gip insulin secretion insulin sensitivity
clinical outcomes of hypervirulent carbapenem-resistant klebsiella pneumoniae infection

Conditions: Infection, Bacterial

Summary: the goal of this observational study is to learn about the risk factors of mortality for crkp infected patients, and to compare the clinical outcomes between hvcrkp infection and ccrkp infection. the main question it aims to answer is • whether hypervirulence would add value to ccrkp infection and cause worse outcomes? participants data will be collected through medical records.

we conducted an observational cohort study comprising three-year (2019-2022) data in a chinese university hospital. we performed genome sequencing for crkp strains, compared adult patients infected by hvcrkp with those by non-hypervirulent "classical" crkp (ccrkp), and used propensity score matching (psm) for imbalanced baseline characteristics. we defined 30-day all-cause and attributed mortalities and 30-day ranking outcomes (death, no response/progress, remission) as primary outcomes and post-infection stay and survival as secondary outcomes. we constructed mortality-predicting models and performed subgroup analyses for crkp of the dominant sequence or capsular type or with varied virulence profiles and for patients with bloodstream or lower respiratory tract infections.

Eligibility criteria:
inclusion criteria: * adult patients (≥18-year-old) with crkp infections were included. exclusion criteria: * younger than 18 years old; clinical samples were identified to contain crkp but were sentenced to be colonization

Keywords: klebsiella pneumoniae hypervirulent clinical outcome
human menstrual blood-derived mesenchymal stem cells for patients with liver cirrhosis

Conditions: Liver Cirrhosis; Fibrosis; Liver Disease; Digestive System Disease

Summary: orthotopic liver transplantation (olt) is currently the most effective method for end-stage liver diseases. however, the critical shortage of donor organs, high cost, and the problem of immune rejection limit its clinical application, and even some patients on the waiting list will never survive to receive a matched liver. stem cell transplantation instead of conventional medical therapy or orthotopic liver transplantation will be a promising alternate approach to regenerate damaged hepatic mass. adult mesenchymal stem cells (mscs) are generally thought of as an autologous source of regenerative cells in previous studies.in this study, the safety and efficacy of menstrual blood-derived stem cells transplantation for patients with liver cirrhosis will be evaluated.

the purpose of this study is to show whether menstrual blood-derived stem cells can improve the disease conditions in patients with liver cirrhosis. one of two treatment arms will be assigned to the patients. one group will receive 2 weeks of conventional therapy plus menscs treatment; the other group will receive 2 weeks of conventional therapy plus placebo treatment. menscs will be cultured and collected in a gmp lab. patients were strictly monitored after the cells injection via i.v.. patients are followed up at intervals up to at least 2 years.clinical parameters such as ascites volume,serum alanine aminotransferase,total bilirubin,prothrombin time,albumin,meld score,and child-pugh score will be evaluated at each timepoint.

Eligibility criteria:
inclusion criteria: * written informed consent * aged 20 to 50years * liver cirrhosis * negative pregnancy test exclusion criteria: * pregnant or lactating women * malignancies * sepsis * vital organs failure * severe bacteria infection * vascular thromboses in the portal or hepatic veins

Keywords: menstrual blood mesenchymal stem cell liver cirrhosis
sc0191 plus chemotherapy in advanced ovarian canceradvanced ovarian cancer

Conditions: Serous Ovarian Cancer; Advanced Ovarian Cancer

Summary: a phase ib/ii clinical study on the safety, pharmacokinetic characteristics, and preliminary efficacy of sc0191 combination chemotherapy in patients with advanced ovarian cancer.

the phase 1b/2,multicenter, open-label study, contains 2 parts. part 1 dose escalation of sc0191 combination chemotherapy: part 1 will estimate the rp2d in dose escalation cohorts in patients withadvanced ovarian cancer. part 2 dose expansion of sc0191 plus chemotherapy.

Eligibility criteria:
inclusion criteria: 1. histologically or cytologically confirmed advanced ovarian cancer that has failed or intolerant or not applicable to standard treatment (applicable to the dose escalation phase of stage ib); 2. histologically or cytologically confirmed advanced high-grade serous ovarian cancer, platinum-resistant or platinum-refractory recurrent ovarian cancer (applicable to the dose expansion phase of stage ii); 3. there is at least one measurable lesion that meets the definition of recist 1.1; 4. voluntarily participate in clinical trials and sign informed consent; 5. age ≥18 years; 6. ecog score of 0 to 1; 7. predicted life expectancy ≥3 months; 8. adequate bone marrow, liver biochemistry, renal function, and coagulation status. 9. female patients who agree to use adequate contraceptive measures. exclusion criteria: 1. received chemotherapy, radiotherapy, immunotherapy or biological therapy, steroid therapy or other investigational drugs \<28 days prior to the first dose of study treatment. 2. patients who have not fully recovered from surgery according to the investigator's judgment.; 3. patients who have previously received wee1 inhibitor treatment; 4. unresolved aes or toxicities due to previous treatments; 5. patients with contraindications or a history of severe allergies to gemcitabine or paclitaxel; 6. known malignant cns disease other than neurologically stable, treated brain metastases; 7. other medical conditions or systemic diseases not suitable to participate; 8. the need for long-term therapeutic doses of anticoagulant or antiplatelet drugs; 9. received cyp3a4 moderate or strong inhibitors or cyp3a4 moderate or strong inducers within 14 days; 10. pregnant or lactating women.
a retrospective real-life data study to assess the exacerbations and lung function in chronic obstructive pulmonary disease ( copd ) patients receiving fluticasone/salmeterol comparing to those εscalating in open-triple fluticasone/salmeterol, long acting muscarinic antagonist (lama) combination

Conditions: COPD; COPD Exacerbation

Summary: inhaled corticosteroid (ics)/long-acting β2-agonist (laba) combination is commonly prescribed to treat copd; we will perform a retrospective analysis on the effect of adding a long-acting muscarinic receptor antagonist (lama) to ics/laba combination in copd.

according to the current guidelines for the treatment of copd, it is recommended to use combination therapies with different or complementary mechanisms of action . data suggest that open triple therapy incorporating lama with ics / laba combination products administered through different delivery devices may be beneficial for improving pulmonary function in patients with copd. however, there is little evidence of the effect of triple therapy on pulmonary function and the incidence of exacerbations in copd patients.

Eligibility criteria:
inclusion * patients with copd who started treatment with a fixed combination of fluticasone / salmeterol via the elpenhaler® device after 01/01/2012 and were treated continuously for at least 1 year during the recording period. * patients for whom spirometric data are available per monitoring year during recording. * patients for whom exacerbation data are available per monitoring year during recording. exclusion •patients with asthma
rct comparing invisalign and traditional orthodontic treatment

Conditions: Malocclusion, Angle Class II

Summary: comparison of orthodontic patients treated with aligners and traditional (clear braces)

patients were selected based on being adults and having mild class i malocclusion. they were randomly allocated into either the aligner group and the traditiona (clear braces group).. the aligner group was treated with invisalign, with up to two adjustments at the end of treatment. the traditional group had clear braces placed on their teeth. the outcome variables including the following: 1) pain and discomfort related to treatment, 2) posttreatment occlusal status, and 3) postretention occlusal status.

Eligibility criteria:
inclusion criteria: 1. class i molar and canine relationships 2. non-extraction treatments 3. mandibular crowding of 4 mm or less 4. no missing tooth (from second to second molar) exclusion criteria: 1. anterior or posterior crossbites 2. anterior or lateral open bites 3. maxillary overjet exceeding 3mm 4. impacted tooth
impact of hypothalamic gliosis on appetite regulation and obesity risk in children

Conditions: Obesity, Childhood

Summary: beam is a multi-site longitudinal cohort study of hypothalamic gliosis, central regulation of appetite and weight gain in children. participants will be recruited from the community in the greater seattle and greater baltimore area. all participants will consent to enroll in the 24-month study during which they will complete 5 in-person study visits.

the proposed 2-site research study uses a longitudinal cohort design in 102 children aged 9-11 yr. it will include for all participants baseline mri and functional mri, in-depth eating behavior testing, and measurement of hormone profiles. serial measurement of weight and self-reported eating habits will occur over 2 yr, with a repeated mri at 2 yr. the study aims to: 1) test if mbh gliosis is associated with impaired intake regulation and poor weight outcomes over 2 yr in children, 2) determine if cns appetitive processing is negatively affected when evidence of mbh gliosis is present, and 3) test for other brain regions in which gliosis is present in association with excess adiposity in children. an exploratory aim will assess changes in gliosis in children over 2 yr and their relation to changes in body weight and adiposity.

Eligibility criteria:
inclusion criteria: * 9-11 y (at time of enrollment) * bmi ≥ 15th percentile for age and sex exclusion criteria: * significant health conditions (e.g., type 2 diabetes) * documented cognitive disorder * history of major weight loss of 10lbs or more, not due to illness, over the past year * eating disorder (e.g. anorexia, bulimia) * current use of medications known to alter appetite, body weight or brain response including: anti-epileptics; glucocorticoids; antipsychotics; stimulants for adhd * mri contraindication (e.g. implanted metal, claustrophobia, inability to fit in mri scanner) * weight \>330 pounds (mri limit) * severe food allergies, vegetarian, or vegan, or unable to eat study foods * currently in formal weight loss program
application of cognitive training based on the remind strategy in glioma patients with cognitive impairment

Conditions: Glioma

Summary: the purpose of this study is to form an interdisciplinary team to dynamically evaluate patient cognitive outcomes and develop an individualized cognitive training program for chinese brain tumor patients

adult patients diagnosed with glioma who meet the inclusion criteria will be enrolled in this study. patients admitted to neurosurgery ward 1 and ward 2 will be assigned to the intervention group, while those admitted to neurosurgery ward 3 and ward 4 will serve as the control group. the intervention group will receive cognitive rehabilitation training based on the remind strategy in addition to standard rehabilitation care, whereas the control group will receive only standard rehabilitation care. assessment of patients' cognitive function, quality of life, psychological status, and the effectiveness of cognitive training intervention will be conducted on the first day of admission, one day before discharge, and at the end of the intervention period.

Eligibility criteria:
inclusion criteria: 1. conforming to the diagnostic criteria outlined in the "chinese clinical guidelines for diagnosis and treatment of central nervous system gliomas (2015)" ; 2. patients diagnosed with brain gliomas through histopathological and/or cytological examination; 3. moca (montreal cognitive assessment) score ≤ 26; 4. karnofsky performance status (kps) score ≥ 60, with no history of past illnesses; 5. age ≥ 18 years; 6. clear consciousness; 7. willingness to participate and signed informed consent form. exclusion criteria: 1. diagnosed with neurological or psychiatric disorders within the past two years; 2. impaired consciousness; 3. accompanied by severe complications such as infections; 4. nursing delirium screening checklist (nu-desc) score ≥ 2; 5. patients with changes in condition or requiring repeat surgery; 6. patients with multiple intracranial tumors; 7. inability to effectively complete the questionnaire or withdrawal during the study.

Keywords: cognitive training cognitive impairment quality of life
study of repetitive intestinal lavage in patients with ehec associated hemorrhagic colitis

Conditions: Hemolytic Uremic Syndrome; Hemorrhagic Colitis; Intestinal Infectious Disease; Intestinal Infection Due to E. Coli

Summary: the investigators examined the outcome of patients with severe enterohaemorrhagic e. coli (ehec) o104:h4 infection suffering from bloody diarrhoea that were at risk to develop hemolytic uremic syndrome and underwent repetitive whole bowl lavage during hospitalization.

during the 2011 german ehec o104:h4 outbreak, centered in the area of hamburg, 33 patients with ehec associated hemorrhagic colitis were admitted to the first department of medicine of the hamburg university medical centre. the first 12 patients were treated symptomatically and received intravenous rehydration up to three liters daily. prompted by a good clinical response after whole bowel irrigation with polyethylene glycol-solution (peg)in patient 13 all subsequent admitted patients (n=21) were treated with peg-solution ( 2 liters on admission followed by one liter per day during the clinical course). during the hospital course blood work was obtained every day and patients were examined for clinical symptoms. thrombocytopenia below 100.000/microliter was defined as a threshold for initiating therapeutic plasmapheresis to prevent the onset of hemolytic syndrome on an early stage.

Eligibility criteria:
inclusion criteria: * proven ehec o104:h4-infection presence of bloody diarrhoea + at least one of the following serological criteria: * platelet count below 150x10³/ μl but greater than 100x10³/ μl, serum creatine above normal level for age (\> 1.1 -1.3 mg/dl), lactate dehydrogenase (ldh) \> 300 iu/l, leukocytosis ( \> 12x10³/ μl ) and elevated crp (\> 5mg/l), hemoglobin \< 13.8 g/dl for male patients or \< 12.1 g/dl for female patients, respectively or decrease in haptoglobin exclusion criteria: * bloody diarrhoea due to others reasons than ehec o104:h4 infection * thrombocytopenia \< 100x10³/ μl. * hus, defined as platelet count below 100x10³/ μl, anaemia or decrease in haptoglobin and serum creatine above normal level for age

Keywords: ehec o104:h4 german outbreak polyethylene glycol bowel lavage
once weekly subcutaneous ports for the administration of anticoagulants

Conditions: Venous Thromboembolism

Summary: the purpose of this study is to ascertain whether subcutaneous ports are an effective and reliable way to administer the low molecular weight heparin (lmwh) enoxaparin to patients for the prevention or treatment of venous thromboembolism.

subcutaneous ports have recently been used to administer low molecular weight heparin (lmwh) to patients for the prevention or treatment of venous thromboembolism; however, no studies have been performed to evaluate the ports' reliability in delivering this type of drug. hence, it is not known whether absorption of the drug is constant over the seven-day lifespan of the port. although the use of subcutaneous ports is not currently the standard of care, health care providers are more frequently using this as an alternative method to direct injection of lmwh, particularly in pediatric patients. the main advantage of subcutaneous ports is the decreased number of needle sticks when using the ports to administer the medication. however, it is possible that, due to potential repeated bleeding into the subcutaneous space at the port site or other factors, drug absorption may decrease over the seven day lifespan of the port, resulting in a decrease of plasma drug level. subtherapeutic lmwh levels and, hence, ineffective anticoagulation may result. this study's aim is to determine if the current use of subcutaneous ports is a safe, effective and reliable way of administering lmwh for the purpose of anticoagulation.

Eligibility criteria:
inclusion criteria: * subjects receiving once or twice daily dosing of therapeutic doses of subcutaneous enoxaparin. * subject has been on the same dose of enoxaparin for at least one week. * anticipated length of enoxaparin treatment at least 4 weeks. * age ≥ 18 years. * subject demonstration of proper subcutaneous catheter care during one education session with the investigator. exclusion criteria: * chronic renal insufficiency with glomerular filtration rate \< 30 ml/min. * pregnancy * venous thromboembolism within the last 4 weeks.

Keywords: low molecular weight heparin enoxaparin lovenox insuflon subcutaneous catheter once or twice daily dosing of subcutaneous enoxaparin